Cboe Global Markets Reports Trading Volume for October 2026

Cboe reported record October average daily volume of 6.9 million proprietary index-options contracts, up 25.0% year over year; SPX options averaged a record 5.5 million contracts and 0DTE SPX volume a record 3.6 million. Activity was mixed across businesses: multi-listed options fell 10.3% and U.S. on-exchange equities fell 24.4% year over year, while global FX volume rose 9.5%.

Analysis

The key signal is mix, not headline volume: proprietary index options are carrying activity while multi-listed options and on-exchange U.S. equities remain weak. That supports Cboe’s product differentiation, but does not establish higher earnings power until the lagged RPC/net-capture data confirm that incremental SPX/XSP contracts monetize well. Record 0DTE and peak-day activity may reflect episodic volatility and concentrated event risk rather than a durable run-rate; a normalization in volatility could quickly unwind the volume tailwind.

Over the next 1–3 months, verify RPC by product, Cboe’s share of index-options activity, and whether strong index demand persists beyond record days. A second-order risk is that growing 0DTE turnover brings greater scrutiny of market quality and operational resilience, while competing venues such as Nasdaq and MIAX have incentives to contest the flow through product and pricing. Clearing growth is supportive only if it translates into net capture; cleared-trade counts alone do not establish that.

The setup is mildly constructive for Cboe, but the press release is not enough to justify chasing the stock without valuation and price-action context. The contrarian point: activity records can look structurally bullish while weaker listed-options and on-exchange-equity activity reveal a narrower earnings driver than the headline suggests. TMX’s completed Australia divestiture is not, by itself, a fresh earnings catalyst; assess it against TMX’s subsequent reported results rather than the removed volume series.

Key Decisions for Investors

• CBOE: keep a positive watch bias, not an automatic momentum buy. Consider initiating only if the next RPC/net-capture release confirms monetization of index-options growth and activity remains broad across the month rather than concentrated in a few sessions.
• Set a 1–3 month falsification check: reassess the thesis if index-options activity retreats materially from the October pace, RPC weakens, or management commentary indicates that pricing/mix is offsetting volume. Avoid inferring revenue growth from ADV alone.
• Watch Nasdaq and MIAX competitive behavior, alongside any market-quality or regulatory developments around 0DTE. A shift in share or adverse rule change would weaken the differentiation thesis; persistent share gains with stable capture would strengthen it.
• No standalone TMX trade from this release: the Australia metrics were removed after the sale, and the article supplies no post-sale earnings or capital-allocation evidence. Revisit after TMX reports results that clarify the transaction’s financial effect.